Table 3.

Half-lives of HDL proteins in healthy controls (n = 9) and patients with NAFLD (n = 15)

Accession Number	Protein	GO-Molecular Function	Control t½, h ± SD	NAFLD t½, h ± SD
Immune response
P01024	Complement C3	Endopeptidase inhibitor	59.6 ± 20.7	247.3 ± 96.8‡
P10909	Apoprotein J (Clusterin)	Misfolded protein binding	26.6 ± 9.4	24.0 ± 8.8
Antioxidant
P27169	Paraoxonase 1	Antioxidant	260.8 ± 65.6	385.7 ± 122.6*
Lipid metabolism
P02647	Apolipoprotein A-I	Cholesterol transporter	66.7 ± 11.5	51.6 ± 8.9†
P02652	Apolipoprotein A-II	Cholesterol transporter	87.8 ± 24.8	46.4 ± 11.7‡
P06727	Apolipoprotein A-IV	Antioxidant, cholesterol transporter	37.7 ± 7.6	19.9 ± 4.4‡
P02766	Transthyretin	Thyroid hormone-binding protein	39.6 ± 14.4	30.1 ± 9.8
Vitamin transport
P02774	Vitamin D-binding protein	Actin-binding, vitamin transporter activity	45.8 ± 12.12	34.4 ± 5.9*
Acute-phase response
P01009	Alpha-1-antitrypsin	Serine-type endopeptidase inhibitor	40.7 ± 13.4	38.5 ± 11.5
P02765	Alpha-2-HS-glycoprotein	Cysteine-type endopeptidase inhibitor	59.7 ± 30.5	48.4 ± 10.5
P02790	Hemopexin	Metal ion-binding	49.4 ± 12.2	47.9 ± 9.0

Data are means ± SD. NAFLD, nonalcoholic fatty liver disease. Different from controls:

^*P < 0.05,

^†P < 0.005,

^‡P < 0.001 (t test).